| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transcatheter Aortic Valve Replacement | 14 | 2022 | 90 | 5.230 |
Why?
|
| Aortic Valve Stenosis | 16 | 2022 | 177 | 4.310 |
Why?
|
| Angioplasty, Balloon, Coronary | 35 | 2012 | 178 | 3.900 |
Why?
|
| Coronary Artery Disease | 28 | 2020 | 696 | 3.000 |
Why?
|
| Heart Valve Prosthesis Implantation | 9 | 2022 | 164 | 2.640 |
Why?
|
| Coronary Angiography | 47 | 2021 | 866 | 2.580 |
Why?
|
| Drug-Eluting Stents | 20 | 2012 | 51 | 2.570 |
Why?
|
| Cardiac Catheterization | 17 | 2022 | 419 | 2.320 |
Why?
|
| Stents | 22 | 2022 | 657 | 1.900 |
Why?
|
| Aortic Valve | 14 | 2022 | 249 | 1.880 |
Why?
|
| Coronary Restenosis | 18 | 2016 | 42 | 1.710 |
Why?
|
| Heart Valve Prosthesis | 6 | 2020 | 222 | 1.550 |
Why?
|
| Computed Tomography Angiography | 11 | 2021 | 424 | 1.490 |
Why?
|
| Fractional Flow Reserve, Myocardial | 11 | 2021 | 137 | 1.430 |
Why?
|
| Coronary Stenosis | 13 | 2018 | 246 | 1.320 |
Why?
|
| Ultrasonography, Interventional | 12 | 2019 | 119 | 1.260 |
Why?
|
| Myocardial Infarction | 21 | 2013 | 807 | 1.230 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2022 | 2324 | 1.120 |
Why?
|
| Sirolimus | 13 | 2012 | 118 | 1.100 |
Why?
|
| Calcinosis | 5 | 2019 | 241 | 1.090 |
Why?
|
| Coronary Thrombosis | 10 | 2009 | 45 | 1.040 |
Why?
|
| Cardiovascular Agents | 6 | 2012 | 82 | 1.020 |
Why?
|
| Foramen Ovale, Patent | 4 | 2015 | 21 | 1.000 |
Why?
|
| Coronary Vessels | 11 | 2022 | 313 | 0.990 |
Why?
|
| Paclitaxel | 11 | 2012 | 140 | 0.930 |
Why?
|
| Percutaneous Coronary Intervention | 5 | 2019 | 137 | 0.840 |
Why?
|
| Humans | 116 | 2022 | 68618 | 0.830 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2018 | 99 | 0.830 |
Why?
|
| Coronary Occlusion | 2 | 2020 | 12 | 0.800 |
Why?
|
| Plaque, Atherosclerotic | 5 | 2016 | 125 | 0.800 |
Why?
|
| Bioprosthesis | 3 | 2018 | 101 | 0.790 |
Why?
|
| Treatment Outcome | 47 | 2022 | 7029 | 0.760 |
Why?
|
| Prosthesis Design | 17 | 2018 | 301 | 0.710 |
Why?
|
| Heart Valve Diseases | 3 | 2022 | 123 | 0.710 |
Why?
|
| Mitral Valve | 4 | 2018 | 166 | 0.700 |
Why?
|
| Retrospective Studies | 48 | 2021 | 7277 | 0.690 |
Why?
|
| Heparin | 8 | 2017 | 205 | 0.670 |
Why?
|
| Hemodynamic Monitoring | 1 | 2019 | 6 | 0.670 |
Why?
|
| Coronary Disease | 7 | 2008 | 358 | 0.640 |
Why?
|
| Coronary Artery Bypass | 7 | 2022 | 218 | 0.630 |
Why?
|
| Male | 86 | 2022 | 37321 | 0.630 |
Why?
|
| Aged | 63 | 2022 | 14862 | 0.630 |
Why?
|
| Contrast Media | 7 | 2016 | 595 | 0.630 |
Why?
|
| Middle Aged | 67 | 2022 | 21147 | 0.600 |
Why?
|
| Anticoagulants | 6 | 2017 | 356 | 0.600 |
Why?
|
| Female | 82 | 2022 | 38074 | 0.590 |
Why?
|
| Iliac Artery | 2 | 2015 | 44 | 0.590 |
Why?
|
| Septal Occluder Device | 2 | 2015 | 21 | 0.590 |
Why?
|
| Thoracotomy | 1 | 2017 | 25 | 0.570 |
Why?
|
| Autonomic Nerve Block | 1 | 2017 | 15 | 0.570 |
Why?
|
| Secondary Prevention | 3 | 2015 | 291 | 0.570 |
Why?
|
| Peptide Fragments | 6 | 2012 | 483 | 0.570 |
Why?
|
| Hemodynamics | 9 | 2022 | 705 | 0.560 |
Why?
|
| Radial Artery | 2 | 2019 | 43 | 0.560 |
Why?
|
| Ischemic Attack, Transient | 2 | 2015 | 167 | 0.560 |
Why?
|
| Hirudins | 6 | 2012 | 32 | 0.560 |
Why?
|
| Saphenous Vein | 4 | 2009 | 61 | 0.530 |
Why?
|
| Graft Occlusion, Vascular | 4 | 2009 | 73 | 0.530 |
Why?
|
| Acute Coronary Syndrome | 4 | 2017 | 195 | 0.510 |
Why?
|
| Angina Pectoris | 4 | 2013 | 61 | 0.500 |
Why?
|
| Aortography | 1 | 2015 | 72 | 0.500 |
Why?
|
| Hemorrhage | 5 | 2017 | 328 | 0.500 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 214 | 0.490 |
Why?
|
| Time Factors | 24 | 2018 | 4655 | 0.470 |
Why?
|
| Arteries | 2 | 2020 | 108 | 0.460 |
Why?
|
| Cardiovascular Diseases | 7 | 2010 | 940 | 0.460 |
Why?
|
| Machine Learning | 4 | 2019 | 170 | 0.450 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2012 | 373 | 0.450 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2012 | 80 | 0.430 |
Why?
|
| Feasibility Studies | 9 | 2022 | 652 | 0.430 |
Why?
|
| Predictive Value of Tests | 16 | 2020 | 1465 | 0.420 |
Why?
|
| Fluoroscopy | 3 | 2020 | 152 | 0.410 |
Why?
|
| Thrombosis | 6 | 2010 | 218 | 0.410 |
Why?
|
| Risk Assessment | 15 | 2021 | 2007 | 0.400 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 201 | 0.400 |
Why?
|
| Vascular Calcification | 3 | 2019 | 131 | 0.400 |
Why?
|
| Prosthesis Failure | 2 | 2015 | 130 | 0.400 |
Why?
|
| Severity of Illness Index | 17 | 2019 | 1851 | 0.400 |
Why?
|
| Shock, Cardiogenic | 3 | 2018 | 23 | 0.390 |
Why?
|
| Heart | 2 | 2016 | 850 | 0.380 |
Why?
|
| Pulmonary Wedge Pressure | 3 | 2022 | 102 | 0.380 |
Why?
|
| Angina, Unstable | 2 | 2008 | 50 | 0.370 |
Why?
|
| Patient Safety | 1 | 2012 | 202 | 0.350 |
Why?
|
| Aged, 80 and over | 16 | 2022 | 4848 | 0.350 |
Why?
|
| Metals | 6 | 2010 | 100 | 0.340 |
Why?
|
| Ticlopidine | 5 | 2009 | 118 | 0.330 |
Why?
|
| Risk Factors | 18 | 2019 | 5731 | 0.320 |
Why?
|
| Prospective Studies | 12 | 2022 | 3705 | 0.310 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2013 | 31 | 0.310 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 3259 | 0.300 |
Why?
|
| Balloon Occlusion | 1 | 2007 | 22 | 0.290 |
Why?
|
| Prognosis | 9 | 2019 | 2093 | 0.290 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 232 | 0.290 |
Why?
|
| Device Removal | 1 | 2007 | 100 | 0.270 |
Why?
|
| Blood Pressure | 3 | 2022 | 1451 | 0.270 |
Why?
|
| Stroke | 4 | 2015 | 2163 | 0.270 |
Why?
|
| Registries | 8 | 2019 | 733 | 0.270 |
Why?
|
| Preoperative Care | 3 | 2021 | 275 | 0.270 |
Why?
|
| Thermography | 1 | 2005 | 20 | 0.260 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 236 | 0.250 |
Why?
|
| Reproducibility of Results | 10 | 2020 | 2077 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2012 | 536 | 0.230 |
Why?
|
| Recombinant Proteins | 6 | 2012 | 742 | 0.220 |
Why?
|
| Heart Failure | 4 | 2022 | 1180 | 0.220 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 4 | 2019 | 373 | 0.220 |
Why?
|
| ROC Curve | 7 | 2017 | 392 | 0.220 |
Why?
|
| Germany | 4 | 2016 | 67 | 0.210 |
Why?
|
| Vena Cava, Superior | 1 | 2022 | 41 | 0.200 |
Why?
|
| Decision Making | 2 | 2017 | 410 | 0.200 |
Why?
|
| Aneurysm, False | 1 | 2022 | 60 | 0.200 |
Why?
|
| Recurrence | 6 | 2015 | 948 | 0.200 |
Why?
|
| Patient Selection | 4 | 2013 | 592 | 0.190 |
Why?
|
| Catheterization, Peripheral | 2 | 2019 | 38 | 0.190 |
Why?
|
| Heart Atria | 1 | 2022 | 206 | 0.190 |
Why?
|
| Lipids | 2 | 2013 | 298 | 0.190 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2020 | 25 | 0.180 |
Why?
|
| Multimodal Imaging | 2 | 2022 | 62 | 0.180 |
Why?
|
| Tubulin Modulators | 2 | 2012 | 10 | 0.180 |
Why?
|
| Immunosuppressive Agents | 5 | 2012 | 514 | 0.180 |
Why?
|
| Transposition of Great Vessels | 1 | 2020 | 51 | 0.180 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2013 | 116 | 0.170 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2015 | 100 | 0.170 |
Why?
|
| Japan | 1 | 2019 | 68 | 0.170 |
Why?
|
| Catheters | 1 | 2019 | 39 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2019 | 10 | 0.170 |
Why?
|
| Obesity | 2 | 2017 | 1076 | 0.170 |
Why?
|
| Myocardial Ischemia | 3 | 2013 | 172 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2019 | 75 | 0.160 |
Why?
|
| Radiation Dosage | 3 | 2016 | 419 | 0.160 |
Why?
|
| Triiodobenzoic Acids | 2 | 2015 | 28 | 0.160 |
Why?
|
| Cardiac-Gated Imaging Techniques | 2 | 2015 | 60 | 0.160 |
Why?
|
| Patient Care Planning | 2 | 2015 | 108 | 0.150 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 323 | 0.150 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 1753 | 0.150 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2008 | 186 | 0.150 |
Why?
|
| Equipment Design | 3 | 2012 | 500 | 0.150 |
Why?
|
| Myocardial Revascularization | 2 | 2008 | 56 | 0.150 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2008 | 54 | 0.150 |
Why?
|
| Echocardiography | 2 | 2022 | 515 | 0.150 |
Why?
|
| Heart Diseases | 3 | 2009 | 276 | 0.150 |
Why?
|
| Ventricular Function, Right | 1 | 2018 | 103 | 0.150 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 83 | 0.150 |
Why?
|
| Coronary Circulation | 3 | 2013 | 136 | 0.140 |
Why?
|
| Adult | 12 | 2022 | 21403 | 0.140 |
Why?
|
| Incidence | 6 | 2013 | 1603 | 0.140 |
Why?
|
| Survival Rate | 5 | 2017 | 1056 | 0.140 |
Why?
|
| South Carolina | 2 | 2013 | 2752 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 2223 | 0.130 |
Why?
|
| Thrombectomy | 2 | 2009 | 238 | 0.130 |
Why?
|
| Everolimus | 2 | 2012 | 26 | 0.130 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 221 | 0.130 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2015 | 93 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2017 | 2358 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 481 | 0.120 |
Why?
|
| Ethanol | 2 | 2013 | 893 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 60 | 0.120 |
Why?
|
| Forecasting | 1 | 2015 | 277 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 42 | 0.110 |
Why?
|
| Embolism, Paradoxical | 1 | 2013 | 6 | 0.110 |
Why?
|
| Disease Progression | 3 | 2019 | 1038 | 0.110 |
Why?
|
| Logistic Models | 6 | 2016 | 1420 | 0.110 |
Why?
|
| Troponin I | 2 | 2011 | 34 | 0.110 |
Why?
|
| Blood Flow Velocity | 1 | 2013 | 172 | 0.110 |
Why?
|
| Ablation Techniques | 1 | 2013 | 33 | 0.110 |
Why?
|
| Deep Sedation | 1 | 2012 | 11 | 0.110 |
Why?
|
| Anesthesia, Local | 1 | 2012 | 14 | 0.110 |
Why?
|
| Sympathectomy | 1 | 2012 | 24 | 0.110 |
Why?
|
| Angiography | 1 | 2013 | 194 | 0.100 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2012 | 6 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2011 | 1615 | 0.100 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 1046 | 0.100 |
Why?
|
| Embolism, Cholesterol | 1 | 2011 | 3 | 0.100 |
Why?
|
| Electrocardiography | 3 | 2009 | 601 | 0.100 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 65 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 689 | 0.100 |
Why?
|
| Acute Disease | 3 | 2009 | 658 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2012 | 119 | 0.100 |
Why?
|
| Creatine Kinase, MB Form | 2 | 2008 | 20 | 0.100 |
Why?
|
| Area Under Curve | 3 | 2016 | 238 | 0.100 |
Why?
|
| Fellowships and Scholarships | 1 | 2012 | 127 | 0.090 |
Why?
|
| Vascular Patency | 3 | 2019 | 122 | 0.090 |
Why?
|
| Angioplasty | 1 | 2011 | 118 | 0.090 |
Why?
|
| Cardiology | 1 | 2012 | 140 | 0.090 |
Why?
|
| Reoperation | 2 | 2009 | 467 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2012 | 229 | 0.090 |
Why?
|
| Diabetes Complications | 2 | 2008 | 249 | 0.090 |
Why?
|
| Tomography, Spiral Computed | 1 | 2009 | 57 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 50 | 0.080 |
Why?
|
| Proportional Hazards Models | 5 | 2009 | 792 | 0.080 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2009 | 14 | 0.080 |
Why?
|
| Biomarkers | 5 | 2019 | 1593 | 0.080 |
Why?
|
| Suction | 1 | 2009 | 33 | 0.080 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 122 | 0.080 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2009 | 14 | 0.080 |
Why?
|
| Femoral Artery | 1 | 2009 | 139 | 0.080 |
Why?
|
| Safety | 2 | 2007 | 145 | 0.080 |
Why?
|
| Emergencies | 1 | 2009 | 107 | 0.080 |
Why?
|
| Embolism | 1 | 2008 | 45 | 0.080 |
Why?
|
| Filtration | 1 | 2008 | 61 | 0.080 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2008 | 4 | 0.080 |
Why?
|
| Tomography, Optical Coherence | 1 | 2009 | 88 | 0.080 |
Why?
|
| Iopamidol | 1 | 2008 | 37 | 0.080 |
Why?
|
| Length of Stay | 1 | 2012 | 780 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2009 | 137 | 0.080 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 85 | 0.080 |
Why?
|
| Heart Septum | 1 | 2008 | 84 | 0.080 |
Why?
|
| Integrin beta3 | 1 | 2008 | 35 | 0.080 |
Why?
|
| Hospital Mortality | 4 | 2013 | 384 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2022 | 586 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2016 | 867 | 0.080 |
Why?
|
| Device Approval | 1 | 2007 | 6 | 0.080 |
Why?
|
| Solvents | 1 | 2008 | 109 | 0.070 |
Why?
|
| Myocardial Contraction | 1 | 2009 | 383 | 0.070 |
Why?
|
| Kidney | 1 | 2012 | 945 | 0.070 |
Why?
|
| Creatinine | 1 | 2008 | 243 | 0.070 |
Why?
|
| Equipment Safety | 1 | 2007 | 50 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2008 | 174 | 0.070 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2007 | 37 | 0.070 |
Why?
|
| Odds Ratio | 3 | 2016 | 880 | 0.070 |
Why?
|
| Radiography, Interventional | 1 | 2007 | 49 | 0.070 |
Why?
|
| United States | 5 | 2017 | 7367 | 0.070 |
Why?
|
| Hypolipidemic Agents | 1 | 2007 | 82 | 0.070 |
Why?
|
| Contraindications | 1 | 2007 | 52 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2007 | 85 | 0.070 |
Why?
|
| Atherectomy, Coronary | 1 | 2006 | 5 | 0.070 |
Why?
|
| Atrial Fibrillation | 1 | 2009 | 249 | 0.070 |
Why?
|
| Comorbidity | 4 | 2013 | 1426 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2012 | 657 | 0.070 |
Why?
|
| Hospitalization | 2 | 2010 | 978 | 0.070 |
Why?
|
| Algorithms | 3 | 2018 | 1196 | 0.070 |
Why?
|
| Thrombolytic Therapy | 1 | 2008 | 233 | 0.070 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 159 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2010 | 1738 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2009 | 377 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2008 | 402 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2008 | 307 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 365 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 378 | 0.060 |
Why?
|
| District of Columbia | 3 | 2009 | 23 | 0.060 |
Why?
|
| Catheterization | 1 | 2005 | 209 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 234 | 0.060 |
Why?
|
| Insulin | 1 | 2008 | 619 | 0.060 |
Why?
|
| Heart Ventricles | 1 | 2009 | 738 | 0.060 |
Why?
|
| Chronic Disease | 3 | 2019 | 1330 | 0.060 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2014 | 47 | 0.050 |
Why?
|
| Hypertension | 1 | 2012 | 1535 | 0.050 |
Why?
|
| Prevalence | 1 | 2007 | 1619 | 0.050 |
Why?
|
| Sternotomy | 1 | 2022 | 18 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2018 | 506 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 694 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2015 | 453 | 0.050 |
Why?
|
| Young Adult | 3 | 2022 | 5717 | 0.050 |
Why?
|
| Ulnar Artery | 1 | 2019 | 2 | 0.040 |
Why?
|
| Vasoconstriction | 1 | 2019 | 81 | 0.040 |
Why?
|
| Lymphangiogenesis | 1 | 2019 | 10 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 59 | 0.040 |
Why?
|
| North America | 1 | 2019 | 112 | 0.040 |
Why?
|
| Benchmarking | 1 | 2019 | 91 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 196 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 649 | 0.040 |
Why?
|
| Adolescent | 3 | 2022 | 8912 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2019 | 134 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 211 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 169 | 0.040 |
Why?
|
| Hydrodynamics | 1 | 2018 | 15 | 0.040 |
Why?
|
| Retreatment | 2 | 2007 | 59 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 1 | 2017 | 57 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 189 | 0.040 |
Why?
|
| Age Factors | 2 | 2013 | 1864 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 334 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2008 | 737 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2015 | 5 | 0.030 |
Why?
|
| Radiation Exposure | 1 | 2016 | 84 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 186 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 78 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 138 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 281 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 172 | 0.030 |
Why?
|
| Sesquiterpenes | 1 | 2014 | 41 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2015 | 181 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2008 | 1553 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2013 | 57 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 333 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2007 | 931 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1745 | 0.030 |
Why?
|
| Adenosine | 1 | 2013 | 165 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2013 | 219 | 0.030 |
Why?
|
| Radiography | 1 | 2013 | 572 | 0.030 |
Why?
|
| Office Visits | 1 | 2012 | 83 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2012 | 89 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2011 | 46 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2012 | 223 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2012 | 174 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 239 | 0.020 |
Why?
|
| Cineangiography | 1 | 2009 | 15 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2009 | 30 | 0.020 |
Why?
|
| Platelet Count | 1 | 2010 | 100 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2009 | 63 | 0.020 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2009 | 20 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 2009 | 97 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 196 | 0.020 |
Why?
|
| Contusions | 1 | 2008 | 11 | 0.020 |
Why?
|
| Observation | 1 | 2008 | 30 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 88 | 0.020 |
Why?
|
| Creatine | 1 | 2008 | 30 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 349 | 0.020 |
Why?
|
| Social Class | 1 | 2009 | 127 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 498 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1342 | 0.020 |
Why?
|
| Injections | 1 | 2008 | 119 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 215 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 216 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 242 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 567 | 0.020 |
Why?
|
| Drug Labeling | 1 | 2007 | 32 | 0.020 |
Why?
|
| Cause of Death | 1 | 2008 | 241 | 0.020 |
Why?
|
| Aspirin | 1 | 2009 | 295 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 714 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 546 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1140 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2009 | 596 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2009 | 665 | 0.010 |
Why?
|
| Research Design | 1 | 2007 | 729 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 772 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 20881 | 0.010 |
Why?
|